Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders

Human Psychopharmacology

Volumn 26, Issue 8, 2011, Pages 602-608

  Yasui Furukori, Norio ^a   Nakagami, Taku ^a   Kaneda, Ayako ^a   Inoue, Yoshimasa ^b   Suzuki, Akihito ^c   Otani, Koichi ^c   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b MP Techno Pharma   (Japan)

^c YAMAGATA UNIVERSITY   (Japan)

Author keywords

concentration; correlation; depression; paroxetine

Indexed keywords

BROTIZOLAM; DIAZEPAM; PAROXETINE; SENNOSIDE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; ANXIETY DISORDER; ARTICLE; BLOOD LEVEL; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 83855165213     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1252     Document Type: Article

References (38)

1. Abela JR, Skitch SA, Auerbach RP, et al,. 2005. The impact of parental borderline personality disorder on vulnerability to depression in children of affectively ill parents. J Pers Disord 19: 68-83.
2. Amdisen A,. 1977. Serum level monitoring and clinical pharmacokinetics of lithium. Clin Pharmacokinet 2: 73-92.
3. Amdisen A,. 1980. Serum concentration and clinical supervision in monitoring of lithium treatment. Ther Drug Monit 2: 73-83.
4. Amsterdam J, Brunswick D, Mendels J,. 1980. The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels. Am J Psychiatry 137: 653-662.
5. Antonijevic IA,. 2006. Depressive disorders-is it time to endorse different pathophysiologies? Psychoneuroendocrinology 31: 1-15.
6. Arias B, Gutiérrez B, Pintor L, et al,. 2001. Variability in the 5-HT(2A) receptor gene is associated with seasonal pattern in major depression. Mol Psychiatry 6: 239-242.
7. Browne TR, 1978. Drug therapy reviews: clinical pharmacology of antiepileptic drugs. Am J Hosp Pharm 35: 1048-1056.
8. Burrows GD, McIntyre IM, Judd FK, et al,. 1988. Clinical effects of serotonin reuptake inhibitors in the treatment of depressive illness. J Clin Psychiatry 49 (Suppl): 18-22.
9. Caspi A, Sugden K, Moffitt TE, et al,. 2003. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301: 386-389.
10. Danish University Antidepressant Group. 1990. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 18: 289-299.
11. Freeman DJ, Oyewumi LK,. 1997. Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin Pharmacokinet 32: 93-100.
12. Gerstenberg G, Aoshima T, Fukasawa T, et al, 2003. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology 167: 443-448.
13. Gilles M,., Deuschle M, Kellner S,. et al. 2005. Paroxetine serum concentrations in depressed patients and response to treatment. Pharmacopsychiatry 38: 118-121.
14. Gunasekara NS, Noble S, Benfield P,. 1998. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 55: 85-120.
15. Haddock RE, Johnson AM, Langley PF, et al,. 1989. Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites. Acta Psychiatr Scand Suppl 350: 24-26.
16. van Harten J,. 1993. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 24: 203-220.
17. Kaye CM, Haddock RE, Langley PF, et al,. 1989. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 350: 60-75.
18. Lamers F, de Jonge P, Nolen WA, et al,. 2010. Identifying depressive subtypes in a large cohort study: results from the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry 71: 239-243.
19. Lieberman R, McMichael J,. 1996. Role of pharmacokinetic-pharmacodynamic principles in rational and cost-effective drug development. Ther Drug Monit 18: 423-428.
20. Lieberman R, Nelson R,. 1993. Dose-response and concentration-response relationships: clinical and regulatory perspectives. Ther Drug Monit 15: 498-502.
21. Lingjaerde O, Ahlfors UG, Bech P, et al,. 1987. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334: 1-100.
22. Meyer JH, Wilson AA, Sagrati S, et al,. 2004. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161: 826-835.
23. Montgomery SA, Asberg M,. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-938.
24. Müller MJ, Dragicevic A, Fric M, et al,. 2003. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmacopsychiatry 36: 98-104.
25. Normann C, Hörn M, Hummel B, et al,. 2004. Paroxetine in major depression: correlating plasma concentrations and clinical response. Pharmacopsychiatry 37: 123-126.
26. Perry PJ, Pfohl BM, Holstad SG,. 1987. The relationship between antidepressant response and tricyclic antidepressant plasma concentrations. A retrospective analysis of the literature using logistic regression analysis. Clin Pharmacokinet 13: 381-392.
27. Perry PJ, Zeilmann C, Arndt S,. 1994. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 14: 230-240.
28. Pfuhlmann B, Gerlach M, Burger R, et al,. 2007. Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice. J Neural Transm Suppl 72: 287-296.
29. van Praag HM,. 2008. Kraepelin, biological psychiatry, and beyond. Eur Arch Psychiatry Clin Neurosci 258 (Suppl 2): 29-32.
30. Rodighiero V,. 1989. Therapeutic drug monitoring of cyclosporin. Practical applications and limitations. Pharmacokinet 16: 27-37.
31. Suzuki A, Aoshima T, Fukasawa T, et al,. 2005. A three-factor model of the MADRS in major depressive disorder. Depress Anxiety 21: 95-97.
32. Takahashi N, Tomita K, Higuchi T, et al,. 2004. The inter-rater reliability of the Japanese version of the Montgomery-Asberg depression rating scale (MADRS) using a structured interview guide for MADRS (SIGMA). Hum Psychopharmacol 19: 187-192.
33. Task Force on the Use of Laboratory Tests in Psychiatry. 1985. Tricyclic antidepressants-blood level measurements and clinical outcome: an APA Task Force report. Am J Psychiatry 142: 155-162.
34. Tasker TC, Kaye CM, Zussman BD, et al,. 1989. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand Suppl 350: 152-155.
35. Watanabe T, Ueda M, Saeki Y, et al,. 2007. High plasma concentrations of paroxetine impede clinical response in patients with panic disorder. Ther Drug Monit 29: 40-44.
36. Yasui-Furukori N, Saito M, Inoue Y, et al,. 2007a. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. Eur J Clin Pharmacol 63: 51-56.
37. Yasui-Furukori N, Saito M, Niioka T, et al,. 2007b. Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. Ther Drug Monit 29: 45-48.
38. Zar JH,. 2010. Biostatistical Analysis, 5th edn. Pearson Prentice Hall, Pearson Education Ins.: USA.